SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the pricing of its upsized initial public offering of 17,640,000 shares of its common stock at an initial public offering price of $18.00 per share.

加利福尼亚州南旧金山，2026年10月22日（环球电讯社）——Lycia Therapeutics, Inc.（“Lycia”）（纳斯达克股票代码：LYCA）是一家处于临床阶段的生物技术公司，专注于发现和开发旨在降解致病性细胞外蛋白的新型疗法，初期重点在于治疗自身免疫性疾病、炎症性疾病和过敏性疾病。该公司今日宣布，其扩大规模后的首次公开募股（IPO）已确定定价，发行普通股17,640,000股，每股首次公开发行价格为18.00美元。

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $317.5 million. All shares of common stock to be sold in the offering will be sold by Lycia. In addition, Lycia has granted the underwriters a 30-day option to purchase up to an additional 2,646,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

在扣除承销折扣、佣金及其他发行费用之前，本次发行的预计总收益约为3.175亿美元。本次发行中拟出售的所有普通股股份均由Lycia公司出售。此外，Lycia已授予承销商一项为期30天的选择权，允许其以首次公开发行价格（扣除承销折扣和佣金后）额外购买最多2,646,000股普通股。

Lycia’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 23, 2026, under the symbol “LYCA.” The offering is expected to close on October 26, 2026, subject to the satisfaction of customary closing conditions..

Lycia的普通股预计将于2026年10月23日在纳斯达克全球精选市场开始交易，股票代码为“LYCA”。本次发行预计将于2026年10月26日完成，前提是满足惯常的交割条件。

Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager for the offering.

杰富瑞、TD Cowen、Evercore ISI 和古根海姆证券担任此次发行的联席账簿管理人。LifeSci Capital 担任此次发行的被动账簿管理人。

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on October 22, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com..

与这些证券相关的注册声明已提交至美国证券交易委员会，并于2026年10月22日生效。本次发售仅通过招股说明书进行。最终招股说明书的副本可在备妥后从以下机构获取：Jefferies LLC，收件人：股票承销团招股说明书部门，地址：520 Madison Avenue, New York, NY 10022，电话：(877) 821-7388，电子邮件：Prospectus_Department@Jefferies.com；TD Securities (USA) LLC，收件人：Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：TDManualrequest@broadridge.com；Evercore Group L.L.C.，收件人：股权资本市场部，地址：55 East 52nd Street, 35th Floor, New York, NY 10055，电话：(888) 474-0200，电子邮件：ecm.prospectus@evercore.com；或Guggenheim Securities, LLC，收件人：股票承销团部门，地址：330 Madison Avenue, 8th Floor, New York, NY 10017，电话：(212) 518-9544，电子邮件：GSEquityProspectusDelivery@guggenheimpartners.com。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Lycia, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售任何Lycia证券的要约，也不构成购买任何Lycia证券的要约邀请；在任何州或司法管辖区，若根据该州或司法管辖区的证券法，在注册或资格认定之前进行此类要约、邀请或销售属于违法行为，则不得在该州或司法管辖区销售这些证券。

Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended..

任何要约、招揽或购买要约，或任何证券销售，均将根据经修订的《1933年证券法》的注册要求进行。

About Lycia Therapeutics

关于Lycia Therapeutics

Lycia Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. The company has advanced its proprietary LYTAC (Lysosomal Targeting Chimera) platform to generate cataLYTAC degraders, which are designed for repeated catalytic elimination of disease-causing proteins.

Lycia Therapeutics 是一家处于临床阶段的生物技术公司，专注于发现和开发旨在降解致病性细胞外蛋白的新型疗法，初期重点在于治疗自身免疫性疾病、炎症性疾病和过敏性疾病。该公司已推进其专有的 LYTAC（溶酶体靶向嵌合体）平台，以生成 cataLYTAC 降解剂，这些降解剂旨在对致病蛋白进行反复的催化清除。

The company’s lead candidates are LCA-0061, a cataLYTAC degrader of IgE for food allergy and other allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete the autoantibodies that cause Graves’ disease..

公司的主要候选药物包括LCA-0061，一种用于食物过敏及其他过敏性疾病的IgE催化LYTAC降解剂；以及LCA-0321，一种旨在选择性清除导致格雷夫斯病的自身抗体的LYTAC降解剂。

Lycia, headquartered in South San Francisco, was founded on the transformational work of Nobel laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University.

Lycia 总部位于南旧金山，由斯坦福大学化学教授、霍华德·休斯医学研究所研究员、诺贝尔奖得主 Carolyn Bertozzi 博士的变革性研究成果创立。

CONTACT: Company Inquiries:

联系方式：公司咨询：

info@lyciatx.com

info@lyciatx.com

Media:

媒体：

Jennifer Price

詹妮弗·普莱斯

The Grace Group

格雷斯集团

jenprice@gracegroup.us

jenprice@gracegroup.us